FY2028 Earnings Forecast for DNLI Issued By HC Wainwright

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at HC Wainwright boosted their FY2028 EPS estimates for shares of Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will earn $4.16 per share for the year, up from their prior estimate of $3.98. HC Wainwright has a “Buy” rating and a $87.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2029 earnings at $6.29 EPS.

A number of other equities research analysts have also commented on DNLI. William Blair started coverage on Denali Therapeutics in a research report on Friday, January 3rd. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Monday, December 16th. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $21.25 on Wednesday. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The firm has a market capitalization of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39. The stock’s 50-day simple moving average is $24.34 and its 200-day simple moving average is $24.88.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the firm posted ($0.72) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after buying an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after acquiring an additional 1,451,770 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Denali Therapeutics during the 2nd quarter valued at about $24,454,000. Wellington Management Group LLP grew its holdings in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the period. Finally, Integral Health Asset Management LLC acquired a new stake in Denali Therapeutics during the second quarter worth about $7,546,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 104,518 shares of company stock worth $2,576,982. 7.90% of the stock is owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.